Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo

Area of Science:

• Endocrinology
• Bone Biology
• Metabolic Research

Background:

• Fat mass influences bone density, but the underlying mechanisms remain unclear.
• Leptin, a peptide hormone produced by adipocytes, is a potential mediator of this relationship.
• Previous studies indicated central leptin administration causes bone loss, contradicting obesity's association with high bone mass.

Purpose of the Study:

• To investigate the direct effects of leptin on bone cells and bone fragility.
• To resolve the discrepancy between central leptin effects and observed bone mass in obesity.
• To determine if peripheral leptin actions on bone could explain the high bone mass in obese individuals.

Main Methods:

• Assessed leptin's effect on osteoblast proliferation and osteoclastogenesis in vitro.
• Examined leptin's impact on mature osteoclast activity.
• Administered leptin systemically to mice and evaluated bone fragility and tibial histomorphometry.

Main Results:

• Leptin stimulated osteoblast proliferation and inhibited osteoclast formation in vitro.
• Systemic leptin administration reduced bone fragility in mice.
• Leptin increased growth plate thickness and chondrocyte proliferation, with both cell types expressing leptin receptors.

Conclusions:

• Direct actions of leptin on bone cells promote bone formation and reduce bone loss.
• Systemic leptin's direct bone effects appear to dominate over central effects, potentially explaining obesity-related high bone mass.
• Leptin's direct effects on bone may contribute to reduced fracture rates in obesity.